New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents

This publication has 45 references indexed in Scilit:

• Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy
  Journal of the Formosan Medical Association, 2013
• Quantitating the subtleties of microglial morphology with fractal analysis
  Frontiers in Cellular Neuroscience, 2013
• Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease
  Cold Spring Harbor Perspectives in Medicine, 2011
• Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
  Investigational New Drugs, 2011
• The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
  Cancer Treatment Reviews, 2011
• Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
  British Journal of Cancer, 2010
• Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours
  British Journal of Cancer, 2010
• A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome
  Thyroid®, 2009
• Vascular disrupting agents in clinical development
  British Journal of Cancer, 2007
• Spindle checkpoint function and cellular sensitivity to antimitotic drugs
  Molecular Cancer Therapeutics, 2006